SCHEMBL836098

SCHEMBL836098

CN(C)c1ccc(-c2cnn3c(-c4cccc(-n5cccn5)c4)cnc3c2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 2/20 0.39
FGFR1 P11362 1/20 0.39
TBK1 Q9UHD2 2/20 0.37
IKBKE Q14164 1/20 0.36
HDAC6 Q9UBN7 1/20 0.35
DYRK1A Q13627 2/20 0.35
ERCC1 P07992 1/20 0.35
ERCC4 Q92889 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA2 P47869 1/20 0.35
METAP2 P50579 1/20 0.34
APP P05067 1/20 0.34
KDM5B Q9UGL1 1/20 0.33
MAPT P10636 1/20 0.33
GRM2 Q14416 1/20 0.33
MAP3K11 Q16584 1/20 0.33
FFAR4 Q5NUL3 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837456 0.83 GABRG2 (0.44) FGFR3FGFR1TBK1IKBKEDYRK1A
SCHEMBL837388 0.82 GRM5 (0.45) FGFR3FGFR1TBK1IKBKEDYRK1A
SCHEMBL835778 0.80 FYN (0.47) FGFR3FGFR1TBK1IKBKEERCC1
SCHEMBL835515 0.78 FGFR1 (0.40) FGFR3FGFR1DYRK1AGABRA1GABRG2
SCHEMBL836435 0.78 CNR2 (0.47) FGFR3FGFR1DYRK1AGRM2
SCHEMBL836898 0.76 FGFR3 (0.67) FGFR3FGFR1TBK1IKBKEERCC1
SCHEMBL835796 0.76 FYN (0.54) DYRK1A
SCHEMBL836396 0.76 FGFR1 (0.43) FGFR3FGFR1TBK1DYRK1AFFAR4
SCHEMBL834911 0.73 FYN (0.49) FGFR3FGFR1TBK1MKNK1
SCHEMBL836708 0.73 FYN (0.40) FGFR3FGFR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143253-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US claimed
EP-2183027-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-08-31 EP claimed
US-20100204235-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-08-12 US claimed
EP-2183027-A1 ORGANIC COMPOUNDS Novartis Ag (CH) 2010-05-12 EP claimed
WO-2009013335-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-01-29 WO claimed
US-8143253-B2 Organic compounds NOVARTIS AG (CH) 2012-03-27 US disclosed
EP-2183027-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-08-31 EP disclosed
US-20100204235-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-08-12 US disclosed
EP-2183027-A1 ORGANIC COMPOUNDS Novartis Ag (CH) 2010-05-12 EP disclosed
WO-2009013335-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204235-A1 ORGANIC COMPOUNDS ALK, OR10J3, FFAR4 FGFR3 81/4885FGFR1 20/4885TBK1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.